Analysts forecast that Chimerix, Inc. (NASDAQ:CMRX – Get Rating) will report earnings of ($0.35) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Chimerix’s earnings. The lowest EPS estimate is ($0.40) and the highest is ($0.23). Chimerix reported earnings per share of ($0.18) in the same quarter last year, which indicates a negative year-over-year growth rate of 94.4%. The firm is scheduled to announce its next earnings report on Monday, January 1st.
On average, analysts expect that Chimerix will report full-year earnings of ($0.11) per share for the current fiscal year, with EPS estimates ranging from ($0.27) to $0.15. For the next financial year, analysts forecast that the firm will post earnings of ($0.06) per share, with EPS estimates ranging from ($0.25) to $0.16. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Chimerix.
Chimerix (NASDAQ:CMRX – Get Rating) last released its earnings results on Tuesday, March 1st. The biopharmaceutical company reported ($0.45) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.34). Chimerix had a negative net margin of 8,753.71% and a negative return on equity of 84.90%. The company had revenue of $0.05 million for the quarter, compared to analyst estimates of $45.06 million. During the same quarter in the previous year, the company earned ($0.19) earnings per share.
NASDAQ CMRX opened at $4.65 on Tuesday. The firm’s 50 day moving average is $5.36 and its 200-day moving average is $5.78. Chimerix has a 12-month low of $4.56 and a 12-month high of $9.29. The company has a market capitalization of $404.69 million, a PE ratio of -2.24 and a beta of 1.34.
Several institutional investors have recently bought and sold shares of CMRX. Marshall Wace LLP bought a new position in shares of Chimerix during the 1st quarter worth about $166,000. Morgan Stanley lifted its position in Chimerix by 55.2% during the second quarter. Morgan Stanley now owns 49,277 shares of the biopharmaceutical company’s stock worth $394,000 after purchasing an additional 17,533 shares during the period. Parametric Portfolio Associates LLC boosted its stake in shares of Chimerix by 26.9% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 22,684 shares of the biopharmaceutical company’s stock valued at $181,000 after purchasing an additional 4,805 shares in the last quarter. PAX Financial Group LLC acquired a new stake in Chimerix during the 3rd quarter worth approximately $198,000. Finally, SG Americas Securities LLC bought a new stake in shares of Chimerix in the 3rd quarter valued at $204,000. Institutional investors and hedge funds own 63.38% of the company’s stock.
Chimerix Company Profile (Get Rating)
Chimerix, Inc, a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox.
- Get a free copy of the StockNews.com research report on Chimerix (CMRX)
- 3 Stocks Near 52-Week Lows Begging to Be Bought
- What’s Going On At Twitter (NYSE: TWTR)?
- MarketBeat Podcast: Making Money In Bull Markets and Bear Markets
- 3 Best Recession-Resistant, Cost-Conscious Retail Stocks to Take a Look at Right Now
- Simply Good Foods Stock is a Healthy Defensive Play
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.